Bendamustine
Chemical compound
Ratings
0
Nobody has rated this yet. Be the first!
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Bendamustine and stem-cell mobilization: not so bad!